Identification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics
Open Access
- 19 March 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (9), 2151-2162
- https://doi.org/10.1158/1078-0432.CCR-19-2942
Abstract
Purpose: Using standard-of-care CT images obtained from patients with a diagnosis of non-small cell lung cancer (NSCLC), we defined radiomics signatures predicting the sensitivity of tumors to nivolumab, docetaxel, and gefitinib. Experimental Design: Data were collected prospectively and analyzed retrospectively across multicenter clinical trials [nivolumab, n = 92, CheckMate017 (NCT01642004), Check-Mate063 (NCT01721759); docetaxel, n = 50, CheckMate017; gefitinib, n = 46, (NCT00588445)]. Patients were randomized to training or validation cohorts using either a 4:1 ratio (nivolumab: 72T:20V) or a 2:1 ratio (docetaxel: 32T:18V; gefitinib: 31T:15V) to ensure an adequate sample size in the validation set. Radiomics signatures were derived from quantitative analysis of early tumor changes from baseline to first on-treatment assessment. For each patient, 1,160 radiomics features were extracted from the largest measurable lung lesion. Tumors were classified as treatment sensitive or insensitive; reference standard was median progression-free survival (NCT01642004, NCT01721759) or surgery (NCT00588445). Machine learning was implemented to select up to four features to develop a radiomics signature in the training datasets and applied to each patient in the validation datasets to classify treatment sensitivity. Results: The radiomics signatures predicted treatment sensitivity in the validation dataset of each study group with AUC (95 confidence interval): nivolumab, 0.77 (0.55-1.00); docetaxel, 0.67 (0.37-0.96); and gefitinib, 0.82 (0.53-0.97). Using serial radiographic measurements, the magnitude of exponential increase in signature features deciphering tumor volume, invasion of tumor boundaries, or tumor spatial heterogeneity was associated with shorter overall survival. Conclusions: Radiomics signatures predicted tumor sensitivity to treatment in patients with NSCLC, offering an approach that could enhance clinical decision-making to continue systemic therapies and forecast overall survival.Other Versions
Funding Information
- NIH (U01 CA225431)
This publication has 55 references indexed in Scilit:
- Semiautomated Volumetric Measurement on Postcontrast MR Imaging for Analysis of Recurrent and Residual Disease in Glioblastoma MultiformeAmerican Journal of Neuroradiology, 2013
- Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinomas: Relationship with CT Characteristics and Histologic SubtypesRadiology, 2013
- SU-E-CAMPUS-J-02: Exploring Appropriate CT Acquisition Parameters for Measuring Tumor Volumes in Response Assessment Using An Anthropomorphic Thorax PhantomMedical Physics, 2013
- Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 MinutesJournal of Clinical Oncology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker DevelopmentClinical Cancer Research, 2010
- Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed Tomography ScansJournal of Thoracic Oncology, 2010
- Evaluating Variability in Tumor Measurements from Same-day Repeat CT Scans of Patients with Non–Small Cell Lung CancerRadiology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- ROC AnalysisAmerican Journal of Roentgenology, 2005